非酒精性脂肪性肝炎相关肝细胞癌中的T细胞驱动因素 - Suppr

T cell drivers in NASH-HCC.

作者信息

O'Leary Karen

机构信息

Nature Reviews Cancer, .

出版信息

Nat Rev Cancer. 2021 Jun;21(6):341. doi: 10.1038/s41568-021-00362-0.

DOI:10.1038/s41568-021-00362-0

PMID:33864034

Abstract

摘要

相似文献

T cell drivers in NASH-HCC.

Nat Rev Cancer. 2021 Jun;21(6):341. doi: 10.1038/s41568-021-00362-0.

Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.

Indian J Med Res. 2019 Jan;149(1):9-17. doi: 10.4103/ijmr.IJMR_1456_17.

Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.

World J Gastroenterol. 2016 Feb 28;22(8):2494-502. doi: 10.3748/wjg.v22.i8.2494.

Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms.

Horm Mol Biol Clin Investig. 2020 Feb 29;41(1):/j/hmbci.2020.41.issue-1/hmbci-2019-0044/hmbci-2019-0044.xml. doi: 10.1515/hmbci-2019-0044.

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.

Can J Gastroenterol Hepatol. 2018 Aug 29;2018:8543763. doi: 10.1155/2018/8543763. eCollection 2018.

Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis.

Carcinogenesis. 2017 Mar 1;38(3):261-270. doi: 10.1093/carcin/bgx005.

Molecular landscape of NASH-HCC.

Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):456. doi: 10.1038/s41575-021-00478-6.

Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.

World J Gastroenterol. 2018 May 14;24(18):1989-1994. doi: 10.3748/wjg.v24.i18.1989.

Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.

Cancer Sci. 2014 Oct;105(10):1254-60. doi: 10.1111/cas.12498. Epub 2014 Sep 25.

Nutrition. 2019 Jun;62:100-107. doi: 10.1016/j.nut.2018.12.001. Epub 2018 Dec 13.

引用本文的文献

Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease liver cancer stem cell activation.

World J Gastroenterol. 2024 Dec 21;30(47):5055-5069. doi: 10.3748/wjg.v30.i47.5055.

Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives.

Clin Mol Hepatol. 2024 Oct;30(4):620-648. doi: 10.3350/cmh.2024.0315. Epub 2024 Jul 11.

Identification of Hub Genes and Immune Infiltration in Non-alcoholic Fatty Liver Disease -Related Hepatocellular Carcinoma by Bioinformatics Analysis.

Turk J Gastroenterol. 2023 Apr;34(4):383-393. doi: 10.5152/tjg.2023.22590.

Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?

Front Immunol. 2022 Oct 28;13:1018962. doi: 10.3389/fimmu.2022.1018962. eCollection 2022.

Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.

Cell Oncol (Dordr). 2023 Feb;46(1):17-48. doi: 10.1007/s13402-022-00741-1. Epub 2022 Nov 11.

Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma.

Front Immunol. 2021 Sep 3;12:729705. doi: 10.3389/fimmu.2021.729705. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

T cell drivers in NASH-HCC.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献